Cellipont Bioservices

Based in California, Cellipont Bioservices provides cell therapy contract development and manufacturing organization services, specializing in CAR-T therapies essential for advancing innovative medical treatments. Cellipont Bioservices, founded in 2002, specializes in contract development and manufacturing for cell therapies. The company is headquartered in The Woodlands, Texas, and has undergone strategic pivots to enhance its focus on advanced therapeutic solutions. The CEO, Devanshu Darji, leads the company in its mission to support biopharmaceutical firms.

Over its operational history, Cellipont has engaged in 3 deals, with the most recent occurring on October 7, 2024. Cellipont Bioservices specializes in providing advanced cell therapy contract development and manufacturing organization (CDMO) services, primarily focusing on the development and production of cell therapies, including CAR-T therapies. Their offerings encompass a wide array of services from process development to commercial manufacturing, crucial for the efficient production of engineered cell therapies. The company's state-of-the-art cGMP manufacturing facility, located in The Woodlands, Texas, enables them to meet stringent regulatory requirements while delivering high-quality therapeutic products.

Cellipont's client base includes biopharmaceutical companies and research institutions that aim to develop life-changing medicines for cancer and other diseases, targeting primarily markets in North America, Europe, and parts of Asia. Cellipont Bioservices generates revenue through business-to-business transactions with pharmaceutical companies and research organizations seeking their CDMO services for cell therapy development and manufacturing. The company engages in structured agreements that may include fixed-price contracts or milestone-based payments, where clients pay at various stages of the project lifecycle, such as during process development, clinical manufacturing, and final product delivery. Specific pricing details for their services are not disclosed, but the company’s offerings, particularly its CAR-T services and tailored manufacturing solutions, serve as the cornerstone of their revenue model.

In October 2024, HealthQuest Capital invested in Cellipont Bioservices to facilitate its expansion of global cell therapy services and enhance operational capabilities. This investment aims to support the launch of new products and the exploration of additional markets, particularly targeting North America and Europe by the end of 2025. The company intends to utilize the acquired funds to strengthen its manufacturing capabilities, ultimately improving its service offerings and addressing the growing demand for cell therapy advancements.